Binder, Michele D., Fox, Andrew D., Laverick, Louise, Foo, Grace, Fabis-Pedrini, Marzena J., Spelman, Timothy, Jordan, Margaret A., Baxter, Alan G., Foote, Simon, , , , Merlo, Daniel, , , , , , , , , , Lechner-Scott, Jeannette, Johnson, Laura J., , , , , , Moscato, Pablo, Scott, Rodney, , , , Giuffrida, Sarah E., , Calvert, Rainer, Akkermann, Rainer, Ma, Gerry Z. M., Perera, Ashwyn A., Gresle, Melissa M.. Public Library of Science (PLoS); 2016. Common and low frequency variants in MERTK are independently associated with multiple sclerosis susceptibility with discordant association dependent upon HLA-DRB1*15:01 status.

Liyanage, Ganesha, Trewin, Benjamin P., Buckland, Ali, Fok, Anthony, Barnett, Michael H., Reddel, Stephen W., Marignier, Romain, El Hajj, Aseel, Monif, Mastura, van der Walt, Anneke, Lechner-Scott, Jeannette, Kermode, Allan G., Lopez, Joseph A., Kalincik, T, Broadley, SA, Dale, RC, Ramanathan, S, Brilot, F, Andersen, Jane, Tea, Fiona, Merheb, Vera, Nguyen, Kristy, Lee, Fiona X. Z., Fabis-Pedrini, Marzena J., Zou, Alicia. BMJ Group; 2024. The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-Associated disease.

Yeh, Wei Z., Van Der Walt, Anneke, Ozakbas, Serkan, Buzzard, Katherine, Habek, Mario, John, Nevin A., Prat, Alexandre, Girard, Marc, Duquette, Pierre, Baghbanian, Seyed Mohammad, Hodgkinson, Suzanne, Van Pesch, Vincent, Skibina, Olga G., Laureys, Guy, Willekens, B, Prevost, J, Foschi, M, De Gans, K, Horakova, D, Havrdova, EK, Karabudak, R, Patti, F, Mccombe, PA, Kalincik, Tomas, Maimone, D, Altintas, A, Ampapa, R, Spitaleri, D, Gerlach, OHH, Sa, MJ, Hughes, S, Gouider, R, Mrabet, S, Macdonell, RA, Alroughani, Raed, Turkoglu, R, Cartechini, E, Al-Asmi, A, Soysal, A, Oh, J, Muros-Le Rouzic, E, Guye, S, Pasquarelli, N, Butzkueven, H, Jokubaitis, VG, Kermode, Allan G., MSBase Study Group,, Fabis-Pedrini, Marzena J., Carroll, William M., Lechner-Scott, Jeannette, Boz, Cavit. Wolters Kluwer Health; 2024. Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies.